Engineered Cell-Derived Vesicles Steer Gene-Editing Cargo to T Cells and Brain Neurons in Mice
Engineered ARRDC1 microvesicles carrying Nipah virus proteins delivered mRNA and base editors to CD8⁺ T cells and PV⁺ neurons in mice.
Summary
Delivering gene-editing tools and mRNA to specific cell types remains a major obstacle in genetic medicine. Researchers at Harvard and collaborators engineered ARRDC1-mediated microvesicles (ARMMs), small vesicles that bud from the cell membrane, by decorating them with modified Nipah virus fusion and attachment proteins linked to targeting ligands. An anti-CD8 antibody fragment directed cargo (protein, mRNA, or a CRISPR base editor) to CD8⁺ T cells, while a DARPin against the GluA4 receptor directed cargo to parvalbumin-positive neurons. In mice, targeted ARMMs achieved functional delivery to CD8⁺ splenocytes and PV⁺ cortical neurons. The work positions surface-engineered ARMMs as a programmable, non-viral platform for precision delivery of RNA and gene-editing therapeutics. The findings are preclinical, and the text supplied here did not include the detailed results sections.
Detailed Summary
Why it matters: Gene editors such as CRISPR-Cas9 and mRNA therapeutics are transforming medicine, but getting them into the right cells without off-target effects is still the central bottleneck. Viral vectors like AAVs have a narrow range of targetable tissues, and lentiviruses integrate into the genome. Lipid nanoparticles (LNPs) can cause toxicity and immune reactions. Extracellular vesicles are a natural, non-viral alternative, but exosomes form inside degradative endosomes and are hard to produce in a controlled way.
What was studied: The team used ARRDC1-mediated microvesicles (ARMMs). These bud directly from the plasma membrane, can be produced in a controlled manner, and can be loaded with protein, mRNA, or CRISPR components during formation. Whether ARMMs could be targeted to specific cell types was unknown. The authors co-expressed in HEK293T producer cells ARRDC1 fused to cargo (GFP, Tat/TAR-EGFP mRNA, Cre recombinase, or the adenine base editor ABE8e with a guide RNA), together with Nipah virus fusion protein (F) and an engineered attachment protein (G). G was mutated to prevent natural receptor binding and fitted with a targeting ligand. The ligands were an anti-CD8 scFv for CD8⁺ T cells, a mouse CD8 DARPin, and a DARPin against the GluA4 receptor for parvalbumin-positive (PV⁺) neurons. Vesicles were purified by ultracentrifugation and iodixanol density gradients and characterized by nano-flow cytometry, Western blotting, and immunogold electron microscopy. Recipient models named in the methods included human PBMCs, mouse splenocytes, iPSCs, and human iPSC-derived glutamatergic neurons.
Key results: According to the abstract, anti-CD8 scFv ARMMs delivered protein, mRNA, or a CRISPR-Cas9 base editor selectively to CD8⁺ T cells. GluA4-DARPin ARMMs enabled delivery to PV⁺ neurons. In mice, administration of targeted ARMMs produced functional delivery to CD8⁺ splenocytes and PV⁺ cortical neurons. Quantitative details such as efficiency, specificity ratios, dosing, and editing rates were not in the text provided, so they are not reported here.
Implications: The results suggest ARMMs can serve as a modular, programmable non-viral delivery system. Swapping the targeting ligand on the Nipah G protein could redirect the same vesicle chassis to other cell types. This could widen options for in vivo T-cell engineering, neuronal gene editing, and RNA medicine, with potentially lower immunogenicity and no genomic integration risk compared with some viral and LNP approaches.
Caveats: This is preclinical work in cell culture and mice. The provided text ended within the Methods, so safety, biodistribution, off-target editing, immunogenicity, durability, manufacturing scalability, and head-to-head comparisons with LNPs or AAVs could not be assessed. One funder and several authors are affiliated with Vesigen Therapeutics, a company developing ARMM technology, which is a potential conflict of interest.
Key Findings
- Nipah virus F and ligand-modified G proteins on ARMM surfaces enabled receptor-specific binding and fusion-mediated cargo release.
- Anti-CD8 scFv ARMMs delivered protein, mRNA, or a CRISPR base editor selectively to CD8⁺ T cells.
- GluA4-targeting DARPin ARMMs delivered cargo to parvalbumin-positive neurons.
- In mice, targeted ARMMs achieved functional delivery to CD8⁺ splenocytes and PV⁺ cortical neurons.
- ARMMs bud from the plasma membrane, avoiding endosomal degradation and allowing controlled, multi-cargo loading.
Methodology
Preclinical study producing ARMMs in HEK293T cells co-transfected with ARRDC1-cargo fusions plus Nipah F and ligand-fitted G proteins, purified by ultracentrifugation and iodixanol gradients and characterized by NanoFCM, Western blot, and immunogold EM. Functional delivery was tested in human PBMCs, mouse splenocytes, iPSCs, and iPSC-derived neurons, then in mice. The supplied text ended within the Methods, so detailed in vitro and in vivo protocols were not available.
Study Limitations
Evidence is limited to cell culture and mouse experiments, and the full results and discussion were not available in the provided text, so effect sizes, specificity, off-target effects, and safety data could not be evaluated. Several authors and a funder are tied to Vesigen Therapeutics, which is developing ARMMs commercially. Scalability, immunogenicity of Nipah-derived proteins, and comparisons with LNPs or AAVs remain untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: